InSCREENeX Appoints Henrik L. Luessen as Chief Business Officer
Henrik L. Luessen brings more than 10 years of business development and strategic planning experience within the biopharmaceutical industry to InSCREENeX. He is founder and Managing Director of Tytonis B.V., a partner within a group of highly experienced, independent advisors providing a broad range of strategic, corporate and business development services to emerging life-science companies (www.tytonis.com). In this role, he supported InSCREENeX during the spin-off process last year.
Besides his roles as Chief Business Officer of InSCREENeX and Managing Director of Tytonis, Dr. Luessen also acts as Chief Business Officer of Activaero GmbH. Prior to founding Tytonis, he worked as Director Business Development at OctoPlus (EuroNext: OCTO), which he helped to develop from a group of 16 employees to a 130 people market leader in biopharmaceutical product development until their IPO in 2006. Before OctoPlus, Henrik L. Luessen was Manager Corporate Development at LTS LOHMANN Therapie Systeme AG, responsible for business development in the field of transdermal delivery systems and new platform technologies worldwide. He obtained his PhD from the Leiden/Amsterdam Center of Drug Research in Pharmaceutical Technology. He is heading the focus group »Pharmaceutical Biotechnology« at the International Association of Pharmaceutical Technology, Germany (APV) and has been serving as Governor of the Executive Board of the European Association of Pharmaceutical Biotechnology (EAPB) since December 2003.
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.